Module 1 Selected Case Studies: NUC-3373 plus pembrolizumab in patients with advanced solid tumors: 72-year-old patient with urothelial bladder cancer who had previously received gemcitabine plus ...

Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Foll ...

For those receiving pembrolizumab, the therapy was initiated at 2-6 weeks ... with all also receiving the immune checkpoint ...

Welcome to the NovoCure Q3 2024 earnings conference call. [Operator instructions] Please be advised that today's conference ...

Q3 2024 Earnings Call Transcript October 30, 2024 NovoCure Limited beats earnings expectations. Reported EPS is $-0.28, expectations were $-0.34. Operator: Good day, and thank you for standing by.

Which adds Roche's immune checkpoint inhibitor atezolizumab to tumor treating ... together with platinum chemotherapy and pembrolizumab, in the first line. LUNAR-4 is setting treatment with ...

A partial clinical hold was placed on the registrational trial after results showed variance between squamous and ...

It is currently being evaluated as a combination treatment with Roche’s Tecentriq (atezolizumab) in an open-label Phase I/II trial (NCT04896697). The study is co-funded by Roche and Xilio and ...

Exelixis will evaluate zanzalintinib in combination with Merck’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab ... in combination with Tecentriq (atezolizumab), for metastatic castration ...